Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Trade receivables and contract assets

v3.25.0.1
Trade receivables and contract assets
12 Months Ended
Dec. 31, 2024
Trade Receivables And Contract Assets [Abstract]  
Trade receivables and contract assets

21. Trade receivables and contract assets

Trade receivables and contract assets are analyzed as follows:

 

 

 

At December 31,

 

 

At December 31,

 

 

 

2024

 

 

2023

 

 

 

(EUR thousand)

 

Trade receivables

 

 

302,655

 

 

 

308,425

 

Allowance for expected credit losses

 

 

(6,704

)

 

 

(6,656

)

Total trade receivables

 

 

295,951

 

 

 

301,769

 

 

 

 

 

 

 

 

 

Trade receivables are non-interest bearing and credit terms are generally 60 to 90 days. The Group is not exposed to significant concentration of third-party credit risk.

Trade receivables breakdown by geographical area is shown below:

 

 

 

At December 31,

 

 

At December 31,

 

 

 

2024

 

 

2023

 

 

 

(EUR thousand)

 

EMEA

 

 

147,675

 

 

 

176,638

 

APAC

 

 

43,989

 

 

 

37,574

 

North America

 

 

101,416

 

 

 

79,529

 

South America

 

 

9,575

 

 

 

14,684

 

Total Trade Receivables

 

 

302,655

 

 

 

308,425

 

 

Trade receivables are stated net of an allowance for expected credit losses which has been determined in accordance with IFRS 9 amounting to EUR 6,704 thousand and EUR 6,656 thousand for 2024 and 2023 respectively:

 

 

 

2024

 

 

2023

 

 

 

(EUR thousand)

 

At January 1

 

 

6,656

 

 

 

5,961

 

Accruals

 

 

1,411

 

 

 

1,489

 

Releases

 

 

(1,346

)

 

 

(807

)

Utilizations

 

 

(25

)

 

 

(21

)

Exchange differences and other changes

 

 

8

 

 

 

34

 

At December 31

 

 

6,704

 

 

 

6,656

 

Contract assets

Contract assets relate to ongoing customer-specific construction contracts within the Engineering segment and from the In-vitro diagnostic and DDS business, which are part of the Biopharmaceutical and Diagnostic Solutions Segment. As such, the balances of this account vary and depend on the number of ongoing construction contracts at the end of the year. The Group had contract assets of EUR 168,515 thousand at December 31, 2024 and of EUR 172,580 thousand at December 31, 2023. Contract assets gross amounted to EUR 414,955 thousand (EUR 360,433 thousand at December 31, 2023), net of advance invoices issued of EUR 246,440 thousand (EUR 187,853 thousand at December 31, 2023).